HSIC241220C80000
- 1.40
- +0.64+84.21%
Henry Schein Newsroom
Biden Proposes Medicare, Medicaid Coverage of Obesity Drugs
Are Wall Street Analysts Bullish on Henry Schein Stock?
Activist Ananym Has a List of Suggestions for Henry Schein. How the Firm Can Help Improve Profits
Henry Schein to Participate in Investor Conferences in December
Hold Rating Maintained for Henry Schein Amid Market Challenges and Activist Investor Influence
Peering Into Henry Schein's Recent Short Interest
Henry Schein To Buy Continuous Glucose Monitors Supplier Acentus
Henry Schein: Acentus Has Annual Revenue of About $35 Million >HSIC
Express News | Henry Schein Inc: Upon Closing, Acentus Founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia Will Join Co
Express News | Henry Schein Inc - Financial Terms Were Not Disclosed
Express News | Henry Schein Inc - Transaction Expected to Be Neutral to 2024 Non-Gaap EPS
Express News | Henry Schein to Acquire Acentus, a Leading Supplier of Homecare Medical Products
Piper Sandler Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $83
Piper Sandler Keeps Their Buy Rating on Henry Schein (HSIC)
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Sector Update: Health Care
Market Chatter: Henry Schein's Activist Investor Seeks Board Overhaul, Divestment, Cost Cuts
Henry Schein Shares Are Trading Higher. The Stock May Be Moving Higher After Activist Investor Ananym Capital Announced Plans for the Company and Began Pushing for Changes.
Express News | Exclusive-Ananym Argues Changes Could Push up Share Price, Earnings
Express News | Exclusive-Ananym Wants Refreshed Board, CEO Succession Plan, Review of Alternatives for Medical Distribution Business -Sources